Please use this identifier to cite or link to this item:
|Title:||Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease||Authors:||Pitchai, Arjun
Rajaretinam, Rajesh Kannan
|Keywords:||Science::Biological sciences||Issue Date:||2020||Source:||Pitchai, A., Rajaretinam, R. K., Mani, R., & Nagarajan, N. (2020). Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease. Heliyon, 6(9), e04930-. doi:10.1016/j.heliyon.2020.e04930||Journal:||Heliyon||Abstract:||Alzheimer's disease (AD), a neurodegenerative disorder affects more than 35 million people globally. Acetylcholinesterase suppression is the common approach to enhance the well-being of AD patients by increasing the duration of acetylcholine in the cholinergic synapses. Generally, herbal secondary metabolites are reported to be a major resource for acetylcholinesterase inhibitors (AChEIs). Trans-tephrostachin was reported from Tephrosia purpurea for AChE inhibition. Here, we report on the design, synthesis, and assessment of human acetylcholinesterase inhibitory activity from trans-tephrostachin derivatives or analogs as anti-AD agents. The five newly synthesized compounds 4a. 4b, 4c, 4d and 4e displayed potent inhibitory activities with IC50 values of 35.0, 35.6, 10.6, 10.3, and 28.1 μM respectively. AChE enzyme kinetic study was performed for the five derived compounds using the Ellman's method. The Lineweaver-Burk and the secondary plots revealed the mixed inhibition for 4a, 4c and 4d whereas 4b and 4e demonstrated competitive inhibition. Molecular docking and molecular dynamics simulations showed the derivatives or analogs of trans-tephrostachin attained a high binding affinity and efficacy than the standard drug. In conclusion, trans-tephrostachin and its derivative compounds could become effective agents for further drug development to treat AD.||URI:||https://hdl.handle.net/10356/145306||ISSN:||2405-8440||DOI:||10.1016/j.heliyon.2020.e04930||Rights:||© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||SoH Journal Articles|
Updated on May 23, 2022
Updated on May 23, 2022
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.